Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
---|---|---|---|---|---|---|
Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
Historisch | Analysen |
11.06.2025 22:00:03
|
EQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting
EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the “General Meeting”), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax (“Board”). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board related to financial transactions. The shareholders have also ratified the appointment of Sylvie Grégoire as Chairman and the appointment of Dominik Höchli, MD as a Board member. Details of the vote results will be available on the Company’s website (www.abivax.com). ***** About Abivax Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at www.abivax.com. Follow us on LinkedIn and on X, formerly Twitter, @ABIVAX. Contacts: Abivax Investor Relations
11.06.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
2153942 11.06.2025 CET/CEST
Nachrichten zu Abivax SA
25.07.25 |
EQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) (EQS Group) | |
24.07.25 |
EQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris (EQS Group) | |
24.07.25 |
EQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares (EQS Group) | |
24.07.25 |
EQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris (EQS Group) | |
23.07.25 |
EQS-News: Abivax Announces Launch of Public Offering (EQS Group) | |
11.06.25 |
EQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting (EQS Group) | |
02.06.25 |
EQS-News: Abivax Presents First Quarter 2025 Financial Results (EQS Group) | |
22.04.25 |
EQS-News: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors (EQS Group) |
Drei neue Aktien kommen in das BX Musterportfolio:
✅ Interactive Brokers – US45841N1072
✅ ING Group N.V. – NL0011821202
✅ Wells Fargo & Co – US9497461015
Drei Aktien verlassen das BX Musterportfolio:
❌ SAP – DE0007164600
❌ Intuit Inc – US4612021034
❌ Deutsche Boerse AG – DE0005810055
Pünktlich zum Börsenstart diskutieren Investment-Stratege François Bloch und Börsen-Experte David Kunz über ausgewählte Top-Aktienwerte aus dem BX Musterportfolio.
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Nach US-Zinsentscheidung: Asiens Börsen uneinheitlichDie Börsen in Asien finden am Donnerstag keine gemeinsame Richtung.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |